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Background 
Human immunodeficiency virus (HIV) is still a problem for global health so, there is a strong need 
to develop effective microbicides that can be used safely to protect from infection during sexual 
intercourse. This pre-exposure prophylaxis (PrEP) may be formulations containing oral or topical 
microbicides. Topical formulations have advantages as they are suitable for vaginal or rectal 
application and allow a higher local concentration of drug. It is recognized that the use of 
electrospun nanofibers for drug carriers is very promising in the biomedical field. So, the objective 
of this study is to develop a novel device for local application of antiretroviral microbicides enabling 
a controlled release of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC), based on 
electrospun polymeric nanofibers.  
Methods 
Based on Truvada®, the aim of this study is to encapsulate TDF and FTC into electrospun polymeric 
nanofibers. Chosen polymers were polycaprolactone (PCL) and poly(vinyl alcohol) (PVA). 
Nanofibers were characterized by SEM, EDS, DSC, among others. Kinetics of the release of the 
drugs from the fibers were studied in vitro. By using different polymers, polymers blends and 
sandwich type it was tried to tailor the release of the drugs. 
Results 
Both morphological (highly porous) and mechanical properties (300% of strain) of the nanofibers 
were adequate for a topical delivery purpose. Drugs were successfully encapsulated in the 
nanofibers and their release was evaluated in different media (aqueous and micellar) and with 
different methodologies (with and without dialysis bag) simulating the physiological conditions and 
confinement at the biological application site. Interaction with mucin revealed suitable 
mucoadhesiveness. 
Conclusion 
Promising results were obtained showing that it is possible to produce a tunable topical delivery 
system based in polymeric nanofibers. 
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